News and Events

Cellomatics BioSciences Ltd collaborates with Krisani Bioscience to advance development of a prodrug compound for the treatment of Nephropathic Cystinosis

Media Release

Cellomatics BioSciences Ltd (www.cellomaticsbio.com) announced its collaboration with Krisani Biosciences (www.krisanibio.com) to advance a novel molecular prodrug conjugate of cysteamine and eicosapentaenoic acid (EPA) for the therapeutic management of nephropathic cystinosis. 

Cysteamine, or 2‐aminoethanethiol, the active pharmaceutical ingredient in PROCYSBI (Horizon Pharma) is used in the treatment of nephropathic cystinosis with potential application in the management of other indications including Huntingdon’s disease, NASH and radiation sickness.

In the announced collaboration, Cellomatics BioSciences and Krisani Biosciences will develop a novel molecular prodrug conjugate of cysteamine and eicosapentaenoic acid (EPA) for the therapeutic management of nephropathic cystinosis. This novel molecular prodrug conjugate of cysteamine and eicosapentaenoic acid (EPA) is patented in the United States.  

On October 25, 2016, Horizon Pharma completed the acquisition of Raptor Pharmaceutical Corp., adding PROCYSBI as an orphan medicine in their portfolio for the treatment of nephropathic cystinosis, a rare metabolic disorder. For the full-year 2016, PROCYSBI total sales were $128.6 million on a combined and adjusted basis.
Cellomatics BioSciences is leading the development of CB-ND-002 portfolio of cysteamine and eicosapentaenoic acid (EPA) conjugates/salts from non-clinical studies to Investigational New Drug Application filing with FDA.  Cellomatics BioSciences has exclusive rights to develop the CB-ND-002 portfolio for global market. 

Ongoing nonclinical studies point to a highly differentiated pharmacokinetic profile as compared to the currently available cysteamine (PROCYSBI) or EPA in plasma. With a flatter pharmacokinetic profile, there is a potential for reduced toxicity and extension of the duration of action. The longer half‐life and AUC of the CB‐ND‐002 produces a superior PK profile which is expected to enhance the efficacy and safety of CB‐ND‐002 when compared to EPA and Cysteamine alone. The collaboration also will advance the IND approved molecules through clinical stage studies, regulatory approval and commercialization of therapy for Nephropathic cystinosis. 

About Cellomatics BioSciences
Cellomatics BioSciences is a laboratory-based Contract Research Organisation providing preclinical in vitro services to support the development of drug compounds and accelerate their progression to the clinical stage of development pipeline. Backed by the company’s expertise in providing preclinical drug development services and as part of its growth strategy, Cellomatics BioSciences is now driving the development of novel drug products for treatment of orphan diseases.  www.cellomaticsbio.com

About Krisani Biosciences 
Krisani Biosciences is an innovative drug design and development biopharmaceutical company focused on enhancing sub‐optimal proven treatments to produce patented superior NMEs/NCEs with a differentiated therapeutic profile.  www.krisanibio.com